WMT

88.74

+1.06%↑

COST

954.14

+0.88%↑

TGT

104.23

-0.08%↓

KR

68.14

+0.84%↑

GIS

59.69

-0.15%↓

WMT

88.74

+1.06%↑

COST

954.14

+0.88%↑

TGT

104.23

-0.08%↓

KR

68.14

+0.84%↑

GIS

59.69

-0.15%↓

WMT

88.74

+1.06%↑

COST

954.14

+0.88%↑

TGT

104.23

-0.08%↓

KR

68.14

+0.84%↑

GIS

59.69

-0.15%↓

WMT

88.74

+1.06%↑

COST

954.14

+0.88%↑

TGT

104.23

-0.08%↓

KR

68.14

+0.84%↑

GIS

59.69

-0.15%↓

WMT

88.74

+1.06%↑

COST

954.14

+0.88%↑

TGT

104.23

-0.08%↓

KR

68.14

+0.84%↑

GIS

59.69

-0.15%↓

Search

Hims & Hers Health Inc

Uždarymo kaina

SektoriusVartotojų apsauga

31 4.55

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

28.71

Max

33.66

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-50M

26M

Pardavimai

80M

481M

P/E

Sektoriaus vid.

54.722

44.466

Pelnas, tenkantis vienai akcijai

0.227

Pelno marža

5.409

Darbuotojai

1,637

EBITDA

-8.2M

19M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+55.4% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-4.7B

6.5B

Ankstesnė atidarymo kaina

26.45

Ankstesnė uždarymo kaina

31

Naujienos nuotaikos

By Acuity

50%

50%

66 / 152 reitingas Consumer defensive

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Hims & Hers Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-01 23:15; UTC

Pagrindinės rinkos jėgos

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2025-02-25 15:33; UTC

Pagrindinės rinkos jėgos

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

2024-11-18 19:07; UTC

Pagrindinės rinkos jėgos

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

2024-10-14 15:02; UTC

Pagrindinės rinkos jėgos

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

2024-10-03 11:28; UTC

Pagrindinės rinkos jėgos

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

2025-03-19 15:54; UTC

Svarbiausios naujienos

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

2025-02-21 23:20; UTC

Uždarbis

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

2025-02-10 12:00; UTC

Svarbiausios naujienos

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

2024-12-19 17:16; UTC

Svarbiausios naujienos

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

2024-12-19 15:14; UTC

Svarbiausios naujienos

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

2024-12-19 15:02; UTC

Svarbiausios naujienos

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

2024-12-16 13:47; UTC

Svarbiausios naujienos

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

2024-12-16 07:00; UTC

Svarbiausios naujienos

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

2024-10-03 14:45; UTC

Svarbiausios naujienos

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

2024-10-03 13:12; UTC

Svarbiausios naujienos

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

2024-10-03 11:45; UTC

Svarbiausios naujienos

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

2024-10-03 10:14; UTC

Svarbiausios naujienos

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2024-08-02 17:52; UTC

Įsigijimai, susijungimai, perėmimai

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

2024-06-26 11:00; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

2024-05-24 20:37; UTC

Uždarbis

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Akcijų palyginimas

Kainos pokytis

Hims & Hers Health Inc Prognozė

Kainos tikslas

By TipRanks

55.4% į viršų

12 mėnesių prognozė

Vidutinis 45.92 USD  55.4%

Aukščiausias 85 USD

Žemiausias 21 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hims & Hers Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

13 ratings

5

Pirkti

6

Laikyti

2

Parduoti

Techninis įvertinimas

By Trading Central

27.22 / 31.88Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

66 / 152 reitingas Vartotojų apsauga

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.